Background. Although the safety and efficacy of @entity13366 ( @entity13366 ) with a five-grass pollen tablet have been demonstrated in randomized clinical trials (RCTs), these outcomes must always be evaluated in real-life medical practice. Methods. In a prospective, open-label, noninterventional, "real-life" study in Germany, we evaluated the safety, tolerability, and effectiveness of @entity13366 with a five-grass pollen tablet in adults with grass-pollen-induced @entity56 . Results. 808 adults were enrolled between September 2008 and December 2009. 35.3% of the @entity1 experienced at least one adverse drug reaction (ADR), the most common of which were mild-to-moderate @entity344 . Serious ADRs considered causally related to @entity13366 treatment occurred in four @entity1 . Overall, the five-grass pollen tablet was considered to have good or very good tolerability by most investigators and @entity1 . Treatment was associated with the relief of nasal, ocular, and bronchial symptoms and decreased symptomatic medication use. However, interpretation of clinical improvements was limited by lower atmospheric grass pollen levels during the study season (relative to the preceding season). Conclusions. In a large population of @entity1 treated in real-life medical practice, @entity13366 with a five-grass pollen tablet was safe and well tolerated. The @entity1 -reported symptom relief suggests that @entity13366 was associated with clinical benefits.

Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult XXXX with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic rhinoconjunctivitis'] @entity13366 :: ('MESH:D013362', 'Disease') :: ['SLIT', 'sublingual immunotherapy'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal and respiratory disorders']
@entity1 :: (9606,Species) :: ['Patients']
